Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

234
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
234
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Liver Retransplantation in Pediatric Recipients: A 20-Year Single-Center Experience With 25 Cases.

Pediatric transplantation·2026
Same author

Educational Effects of Training With a Virtual Reality-Based Objective Structured Clinical Examination Software.

Journal of medical education and curricular development·2026
Same author

Thalidomide for CGD-related inflammatory bowel disease: A randomized, double-blind trial.

Journal of human immunity·2026
Same author

Age-dependent electroclinical evolution from focal seizures to epileptic spasms in NUSAP1-related malformations of cortical development.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Incidental Hepatoblastoma in an Infant Who Underwent Liver Transplantation for Cryptogenic Liver Cirrhosis: A Case Report.

Pediatric transplantation·2026
Same author

X-linked severe combined immunodeficiency with Down syndrome identified by newborn screening.

Journal of human immunity·2026

相关实验视频

Updated: Jan 7, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K

儿科固体瘤的精密瘤使用医院内儿科/AYA恶性瘤特定面板测序.

Masato Kojima1, Sho Kurihara1, Isamu Saeki1

  • 1Department of Pediatric Surgery, Hiroshima University Hospital, Hiroshima, Japan.

Cancer science
|December 29, 2025
PubMed
概括

对于儿科和青少年/年轻成人 (AYA) 癌症的医院内分子分析准确地识别出诊断,预后和可向的变异. 这种方法有助于精确诊断,预测预后,并选择治疗罕见癌症的治疗速度快.

关键词:
青少年 青少年 青少年 青少年在医院内进行测序.分子造型分析 (MOP) 是一种分子造型分析.儿科 儿科 儿科精确瘤学 精确瘤学有针对性的测序面板.年轻的成年人年轻的成年人

更多相关视频

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.9K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K

相关实验视频

Last Updated: Jan 7, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.9K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K

科学领域:

  • 基因组医学是基因组医学.
  • 儿科瘤学 儿科瘤学
  • 分子诊断学 分子诊断学

背景情况:

  • 精密瘤学通过利用瘤基因组概况来彻底改变癌症治疗.
  • 儿科和青少年/年轻成人 (AYA) 恶性瘤代表了罕见的,侵略性的癌症,需要先进的诊断和治疗策略.
  • 分子分析对于了解这些具有挑战性的恶性瘤的遗传基础至关重要.

研究的目的:

  • 评估医院内分子分析对儿科和AYA固体瘤的实用性.
  • 评估针对性测序小组在改善诊断,预后和确定治疗点方面的作用.
  • 确定在临床环境中医院内分子分析的效率和周转时间.

主要方法:

  • 在Oncomine儿童癌症研究试验 (203个基因,1700个融合) 用于分子分析.
  • 分析了153个诊断时的样本和34个复发/耐药的样本,来自165名儿科和AYA患者.
  • 模拟了医院内分子分析,重点关注变体识别,临床意义和周转时间 (TAT).

主要成果:

  • 发现了大量可报告变异 (81.8%),其中33.1%具有临床意义.
  • 临床上显著的变异包括诊断 (13.9%),预后 (9%),可向 (21.9%) 和耐药性 (9.6%) 的变化.
  • 高水平的证据支持诊断和预后变异,在癌症倾向综合征中验证了生殖线突变. 在七个工作日内完成了TAT.

结论:

  • 使用量身定制的测序面板进行医院内分子分析,有效地识别了儿科和AYA恶性瘤的可报告变异.
  • 这种方法促进了准确的诊断,恶性瘤分类,治疗选择和癌症倾向综合征的识别.
  • 医院内分析的快速TAT支持对这些罕见和侵袭性癌症的及时临床决策.